Novartis übernimmt das britische Biotechunternehmen Myricx Bio für bis zu 1,5 Milliarden US-Dollar, um seine Onkologie-Sparte zu stärken. Myricx Bio entwickelt Antikörper-Wirkstoff-Konjugate, die Resistenzen gegen Krebsmedikamente überwinden sollen.
Novartis übernimmt das britische Biotechunternehmen Myricx Bio für bis zu 1,5 Milliarden US-Dollar, um seine Onkologie-Sparte zu stärken. Myricx Bio entwickelt Antikörper-Wirkstoff-Konjugate, die Resistenzen gegen Krebsmedikamente überwinden sollen.
Novartis, kanser tedavisinde hedefli hücre imhası sağlayan yeni nesil ADC platformu geliştiren Myricx Bio'yu 1,5 milyar dolara satın alıyor. Anlaşma, 1,1 milyar dolar peşin ve 400 milyon dolara kadar ek ödeme içeriyor.
Novartis' CEO warned Tuesday that U.S. drug pricing policy under President Donald Trump poses a "very difficult situation."
Novartis, Amgen and Eli Lilly are in late-stage trials for drugs targeting Lp(a), a dangerous form of cholesterol affecting one in five people worldwide. Novartis expects Phase 3 results mid-2026 for pelacarsen, with Amgen and Lilly following in 2027 and 2029. The drugs have shown 80%+ Lp(a) reduction but must now prove clinical benefit. If successful, the market could reach $5.6B by 2032, though less than 1% of U.S. adults currently get tested for Lp(a).
